Secondly, BCL6 was central to a receptor tyrosine kinase inhibitor (TKI) drug-resistance pathway, and BCL6 inhibition eradicated drug-resistant leukemia-initiating cells [15]. This evidence concerns the gene BCL6 and leukemia.